3. 1935
Dr K A Hamied sets up "The Chemical, Industrial and Pharmaceutical
Laboratories Ltd." in a rented bungalow, at Bombay Central.
1941
As the Second World War cuts off drug supplies, the company starts
producing fine chemicals, dedicating all its facilities for the war effort.
1952
Sets up first research division for attaining self-sufficiency in technological
development.
1960
Starts operations at second plant at Vikhroli, Mumbai, producing fine
chemicals with special emphasis on natural products.
1968
Cipla manufactures ampicillin for the first time in the country.
4. 1972
Starts Agricultural Research Division at Bangalore, for scientific cultivation
of medicinal plants.
1976
Cipla launches medicinal aerosols for asthama.
1980
Wins Chemexcil Award for Excellence for exports.
1982
Fourth factory begins operations at Patalganga, Maharashtra.
1984
Develops anti-cancer drugs, vinblastine and vincristine in collaboration with
the National Chemical Laboratory, Pune. Wins Sir P C Ray Award for
developing inhouse technology for indigenous manufacture of a number of
basic drugs.
5. Milestones
1985
US FDA approves Cipla's bulk drug manufacturing facilities.
1988
Cipla wins National Award for Successful Commercialization of Publicly
Funded R&D.
1991
Launches etoposide, a breakthrough in cancer chemotherapy, in association
with Indian Institute of Chemical Technology.The company pioneers the
manufacture of the antiretroviral drug, zidovudine, in technological
collaboration with Indian Institute of Chemical Technology, Hyderabad.
6. 1999
Launches Nevirapine, antiretroviral drug, used to prevent the transmission
of AIDS from mother to child.
2000
Cipla became the first company, outside the USA and Europe to launch
CFC-free inhalers – ten years before the deadline to phase out use of CFC
in medicinal products.
2002
Four state-of-the-art manufacturing facilities set up in Goa in a record time
of less than twelve months.
7. 1994
Cipla's fifth factory begins commercial production at Kurkumbh,
Maharashtra.
1997
Launches transparent Rotahaler, the world's first such dry powder inhaler
device now patented by Cipla in India and abroad. The palliative cancer
care centre set up by the Cipla Foundation, begins offering free services at
Warje, near Pune.
1998
Launches lamivudine, becoming one of the few companies in the world to
offer all three component drugs of retroviral combination therapy
(zidovudine and stavudine already launched).
8. 2003
Launches TIOVA (Tiotropium bromide), a novel inhaled, long-acting
anticholinergic bronchodilator that is employed as a once-daily
maintenance treatment for patients with chronic obstructive pulmonary
disease (COPD).Commissioned second phase of manufacturing operations
at Goa.
2005
Set-up state-of-the-art facility for manufacture of formulations at Baddi,
Himachal Pradesh.
2007
Set-up state-of-the-art facility for manufacture of formulations at Sikkim.
9. To build a healthy India. And along the way realized , that in our own small way ,
we could Contribute to making the world a healthier place. We will continue to
bring a smile on as many faces as we can to heal the world as much as we can.
VISION
10. At Cipla we enjoy challenges and creating change
for the better – for patients and doctors, and for
our own people. Some of our most successful
managers are in their 20s and 30s, and still rising
because they work with energy and passion. If you
are looking for a mission for life, look up our
Careers section
11. “Cipla commits itself to endeavor to satisfy our customers' needs
in every manner possible: through excellent service, by
developing and marketing an effective, safe, quality product and
by offering our product at a price affordable to all patients”
“It is our wish that we be recognized as innovators in the field of
pharmaceutical marketing rather than just followers, be the
investors pick and achieve sustainable above average returns to
the investor”.
“It is our dream that through our policy of dedication and
commitment we will create an environment whereby Cipla will
come to be recognized as the preferred partner in medicine”.
12. CIPLA RESEARCH & DEVELOPMENT
While our skills are among the best in the world, what makes
us different is our multi-disciplinary approach to research.
We believe there’s no use in developing life-saving medicines
if we can’t make them affordable for the patient.
Cipla opened the doors of hope to millions and millions of
patients by becoming the first company in the world to offer
the Triple-Drug AIDS Cocktail for less than a dollar a day. One
out of every three HIV-AIDS patients under treatment in Africa
uses a Cipla drug.
.
13. 2oo8- Active in overseas markets.
Cipla pips Ranbaxy.
Gets Thumbs up for Generic HIV Drug.
2009- retail market grows 15%
Gets Tentative USFDA Approval
Pharmaceuticals Export Promotion Council Awards
Launches generic drug to treat H1N1
2010-piramal healthcare acquires “i-pill” ,a leading
Emergency contraceptive brand from Cipla
Extends an innovative “Mother-Baby Pack” for preventing
mother-to-child transmission of HIV
14.
15. The company posted a net profit of Rs 767 crore for the year ended March 31, 2009,
as compared to Rs 701 crore in the corresponding period last year. Total income
increased from Rs 4,271 crore for the year ended March 31, 2008 to Rs 5,338 crore for
the year ended March 31, 2009.
18. 1. Ethical conduct
All directors and senior management employees shall deal on behalf of the
company with professionalism, honesty, integrity as well as high moral
and ethical standards. Such conduct shall be fair and transparent and be
perceived to be as such by third parties.
2. Conflict of interest
Any director or senior management employee of the Company shall not
engage in any business, relationship or activity, which might detrimentally
conflict with the interest of the Company.
Code of conduct
19. 3. Transparency
All directors and senior management employees of the Company shall
ensure that their actions in the conduct of business are totally transparent
except where the needs of business security dictate otherwise. Such
transparency shall be brought about through appropriate policies, systems
and processes.
4. Legal compliance
All directors and senior management employees of the Company shall at all
times ensure compliance with all the relevant laws and regulations
affecting operations of the Company.
20. 5. Rightful use of company’s assets
All the assets of the Company both tangible and intangible shall be
employed for the purpose of conducting the business for which they are
duly authorized.
6. Cost consciousness
All the directors and senior management employees of the Company
should strive for optimum utilization of available resources. They shall
exercise care to ensure that costs are reasonable and there is no wastage.
21. 7. Confidential information
All directors and senior management employees shall ensure that any
confidential information gained in their official capacity is not utilized for
personal profit or for the advantage of any other person. They shall not
provide any information either formally or informally to the press or to any
other publicity media unless specifically authorized to do so.
8. Relationships with Suppliers and Customers
The Directors and senior management employees of the Company during
the course of interaction with suppliers and customers, shall neither
receive nor offer or make, directly and indirectly, any illegal payments,
remuneration, gifts, donations or comparable benefits which are intended
or perceived to obtain business or uncompetitive favours for the conduct of
its business. However this is not intended to include gifts of customary
nature.
22. 9. Interaction with Media
The Directors and senior management employees other than the
designated spokespersons shall not engage with any member of press and
media in matters concerning the Company. In such cases, they should
direct the request to the designated spokespersons.
10. Safety and Environment
The Director and senior management employees shall follow all prescribed safety and
environmental related norms.
23. World Health Organization
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia
Pharmaceutical Inspection Convention (PIC),
Germany
National Institute of Pharmacy (NIP), Hungary
The Medicines and Healthcare products Regulatory
Agency (MHRA) is the UK government agency
